Cardiac and Pulmonary Management Status of Duchenne Muscular Dystrophy in South Korea Based on Data From the National Health Insurance Database
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose The purpose of this study was to determine the cardiac and pulmonary management status of patients with Duchenne muscular dystrophy (DMD) in South Korea based on the Korean National Health Insurance database. Methods This study used data of patients with code G71.0 in the National Health Information database, and also those with the special case of code V012. Cardiac function was assessed based on whether echocardiography and 24-h electrocardiography were performed, as well as the frequency of these investigations. Furthermore, information on the use of angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB), and beta blockers (BB) in the drug benefit list was checked. Medical charge records were also checked regarding the prescription of respiratory functional assessments and treatments. Results The diagnostic criteria were met by 479 patients, with 41% of these patients receiving a cardiac evaluation, 29.8% being prescribed ACEi at 14.4±3.7 years of age, 59.5% undergoing pulmonary function tests, and 42.1% received pulmonary rehabilitation. The age at receiving ventilator support was 19.4±2.7 years. The frequency of cardiac and respiratory function tests increased with age, but the interval between tests was longer than the recent DMD care recommendations. The trend of taking ACEi, ARB, and BB for cardiac management in South Korea did not change during the study analysis period. Conclusions The findings of this study will contribute to recognizing the current status and the importance of applying an anticipatory approach to cardiopulmonary function in DMD patients
Abstract
Background and Purpose The purpose of this study was to determine the cardiac and pulmonary management status of patients with Duchenne muscular dystrophy (DMD) in South Korea based on the Korean National Health Insurance database. Methods This study used data of patients with code G71.0 in the National Health Information database, and also those with the special case of code V012. Cardiac function was assessed based on whether echocardiography and 24-h electrocardiography were performed, as well as the frequency of these investigations. Furthermore, information on the use of angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB), and beta blockers (BB) in the drug benefit list was checked. Medical charge records were also checked regarding the prescription of respiratory functional assessments and treatments. Results The diagnostic criteria were met by 479 patients, with 41% of these patients receiving a cardiac evaluation, 29.8% being prescribed ACEi at 14.4±3.7 years of age, 59.5% undergoing pulmonary function tests, and 42.1% received pulmonary rehabilitation. The age at receiving ventilator support was 19.4±2.7 years. The frequency of cardiac and respiratory function tests increased with age, but the interval between tests was longer than the recent DMD care recommendations. The trend of taking ACEi, ARB, and BB for cardiac management in South Korea did not change during the study analysis period. Conclusions The findings of this study will contribute to recognizing the current status and the importance of applying an anticipatory approach to cardiopulmonary function in DMD patients
참고문헌 (26)
- Eagle M, "Survival in Duchenne muscular dystrophy : improvements in life expectancy since 1967 and the impact of home nocturnal ventilation", Neuromuscul Disord, 12, pp.926~929 (2002)
- Ogata H, "Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy", J Cardiol, 53, pp.72~78 (2009)
- Vignos PJ Jr, "Respiratory function and pulmonary infection in Duchenne muscular dystrophy", Isr J Med Sci, 13, pp.207~214 (1977)
- Nigro G, "The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy", Int J Cardiol, 26, pp.271~277 (1990)
- Bach JR, "Duchenne muscular dystrophy : continuous noninvasive ventilatory support prolongs survival", Respir Care, 56, pp.744~750 (2011)
- Passamano L, "Improvement of survival in Duchenne muscular dystrophy : retrospective analysis of 835 patients", Acta Myol, 31, pp.121~125 (2012)
- Ishikawa Y, "Duchenne muscular dystrophy : survival by cardio-respiratory interventions", Neuromuscul Disord, 21, pp.47~51 (2011)
- Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmacological and psychosocial management", Lancet Neurol, 9, pp.77~93 (2010)
- Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 2 : implementation of multidisciplinary care", Lancet Neurol, 9, pp.177~189 (2010)
- Birnkrant DJ, "Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management", Lancet Neurol, 17, pp.251~267 (2018)
- Birnkrant DJ, "Diagnosis and management of Duchenne muscular dystrophy, part 2 : respiratory, cardiac, bone health, and orthopaedic management", Lancet Neurol, 17, pp.347~361 (2018)
- Cowen L, "Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry", BMC Neurol, 19, pp.84~ (2019)
- Li X, "A comprehensive database of Duchenne and Becker muscular dystrophy patients(0-18years old)in East China", Orphanet J Rare Dis, 10, pp.5~ (2015)
- Koeks Z, "Clinical outcomes in Duchenne muscular dystrophy : a study of 5345 patients from the TREAT-NMD DMD global database", J Neuromuscul Dis, 4, pp.293~306 (2017)
- Moxley RT 3rd, "Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment : implications for management", J Child Neurol, 25, pp.1116~1129 (2010)
- Takeuchi F, "Clinical practice with steroid therapy for Duchenne muscular dystrophy : an expert survey in Asia and Oceania", Brain Dev, 42, pp.277~288 (2020)
- McNally EM, "New approaches in the therapy of cardiomyopathy in muscular dystrophy", Annu Rev Med, 58, pp.75~88 (2007)
- Cripe LH, "Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy", Paediatr Anaesth, 23, pp.777~784 (2013)
- McNally EM, "Contemporary cardiac issues in Duchenne muscular dystrophy", Circulation, 131, pp.1590~1598 (2015)
- Porcher R, "Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data", Eur Heart J, 42, pp.1976~1984 (2021)
- Epstein AE, "ACC", AHA, American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the ACC, pp.AHA, NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices)developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons[DOI]
- Gomez-Merino E, "Duchenne muscular dystrophy : prolongation of life by noninvasive ventilation and mechanically assisted coughing", Am J Phys Med Rehabil, 81, pp.411~415 (2002)
- McKim DA, "Lung volume recruitment slows pulmonary function decline in Duchenne muscular dystrophy", Arch Phys Med Rehabil, 93, pp.1117~1122 (2012)
- Stehling F, "Mechanical insufflation", exsufflation improves vital capacity in neuromuscular disorders, 2015, pp.12, 31~35
- Chiou M, "Active lung volume recruitment to preserve vital capacity in Duchenne muscular dystrophy", J Rehabil Med, 49, pp.49~53 (2017)
- Tzeng AC, "Prevention of pulmonary morbidity for patients with neuromuscular disease", Chest, 118, pp.1390~1396 (2000)